PLUR - Total Utang marang Modal Pluri

Logo perusahaan publik Pluristem Therapeutics (PLUR)

The market valuation trend for Pluri Inc. (PLUR) based on the total debt-to-equity ratio is 0.00. Pluri Inc. (PLUR) is facing a revenue shortfall due to the slow validation of its 3D cultivation systems' effectiveness, which threatens a financial gap. The business relies on creating scalable cell platforms for therapy and nutrition while struggling with a high burn rate and a history of failed tests.

PLUR: Total Utang marang Modal Pluri Inc 28.04.2023 - 29.10.2026

Rincian analitis perusahaan Pluri Inc.

- rega lan prakiraan konsensus rega:
Bagan rega Pluristem Therapeutics|PLUR - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Pluri|PLUR - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Pluri|PLUR - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku pluri-biotech.com|PLUR - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Pluri Inc.|PLUR - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Pluristem Therapeutics|PLUR - Gunggung utang perusahaan|Utang marang nilai buku Pluri|PLUR - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Pluri|Rasio cepet pluri-biotech.com
- informasi bathi lan kelipatan valuasi:
PLUR - Penghasilan resik perusahaan
Analisis dhasar perusahaan:Pluri Inc.
Barang utama Pluri

For biotech leader Pluri Inc. (PLUR), with its capital-intensive R&D projects in regenerative medicine, controlling the debt load is a key factor for stability. Analyzing the balance between debt and equity, we see a current value of 0.00, which reflects the proportion of total liabilities relative to net assets, determining the risk of liquidity shortages for interest payments and influencing the final fair value of the business.

Analisis pesaing Pluri Inc.

Utang marang Ekuitas Ascendis Pharma|Madrigal Pharmaceuticals Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal CORT|RYTM (Rhythm Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AKRO (Akero Therapeutics)|Total Utang marang Modal metsera.com MTSR|MLTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Utang marang Modal|Total Utang marang Modal 89bio.com|Rasio Total Utang marang Ekuitas AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas MiMedx Group MDXG|RZLT - Rasio Total Utang marang Ekuitas|Lexicon Pharmaceuticals - Total Utang marang Modal|Utang marang Modal mbxbio.com|ALT (Altimmune) - Rasio Total Utang marang Ekuitas|AARD: Utang Agregat marang Modal|SGMT (Sagimet) - Total Utang marang Modal|Total Utang marang Modal BioAge Labs, Inc|Total Utang marang Modal BMEA|Utang marang Ekuitas QNCX (quincetx.com)|Utang marang Ekuitas Fractyl Health GUTS|vTv Therapeutics, Inc. (VTVT) - Utang marang Modal|ATPC - Utang marang Ekuitas|SYBX: Utang marang Ekuitas|LPCN: Total Utang marang Modal|MTNB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Spruce Biosciences, Inc.|Galecto Inc (GLTO) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Carmell Corp (CTCX)|Rasio Total Utang marang Ekuitas Lumos Therapeutics LUMO|Utang marang Ekuitas Organovo Holdings, Inc. ONVO|RDUS (radiuspharm.com) - Utang Agregat marang Ekuitas